J&J | JNJ - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
AbbVie USD 6.57B 2.82B 2026-06
Abbott USD 6.8B 1.72B 2026-03
Amgen USD 13.99B 1.95B 2026-06
AstraZeneca USD 4.89B 2.67B 2026-06
Baxter International USD 2.15B 133M 2026-06
Bayer EUR 4.29B 1.44B 2026-06
Becton, Dickinson and Co. USD 708M 105M 2026-06
Biogen USD 1.28B 2.1B 2026-06
Boston Scientific USD 539M 914M 2026-06
Bristol-Myers Squibb USD 8.72B 852M 2026-06
CONMED USD 35.03M 5.79M 2026-03
Cooper Companies USD 138.8M 13.9M 2026-03
Dexcom USD 1.1B 13.2M 2026-06
Edwards Lifesciences USD 2.9B 500M 2026-06
Eli Lilly USD 8.95B 3.67B 2026-06
Gilead Sciences USD 7.63B 64M 2026-03
GlaxoSmithKline GBP 3.44B 292M 2026-03
Globus Medical USD 507.74M 53.2M 2026-06
Insulet USD 534.9M 54.5M 2026-06
Integra LifeSciences USD 214.42M 22.39M 2026-06
Intuitive Surgical USD 8.63B 646.3M 2026-06
J&J USD 20.42B 1.27B 2026-06
Medtronic USD 1.69B 258M 2026-06
Merck USD 6.85B 1.52B 2026-06
Merit Medical Systems USD 448.7M 39.38M 2026-06
Novartis USD 7.62B 739M 2026-06
Pfizer USD 976M 727M 2026-06
Regeneron Pharmaceuticals USD 2.46B 506.8M 2026-06
Roche Holding CHF 7.55B 579M 2025-06
Sanofi EUR 6.35B 806M 2026-06
Stryker USD 3.39B 513M 2026-06
Tandem Diabetes Care USD 62.82M 116.51M 2026-06
Teva Pharmaceutical Industries USD 3.74B 185M 2026-03
Vertex Pharmaceuticals USD 7.85B 605.7M 2026-06
Zimmer Biomet Holdings USD 410M 14.2M 2026-06
Zoetis USD 1.48B 465M 2026-06